Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 15,616 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin and Connective Tissue Disease Clear all

Conditions: Psoriasis
Interventions: Dermatology-Specific Treatment Satisfaction Instrument; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: AeroForm Tissue Expansion, Saline Tissue Expansion; Device · Procedure
Lead sponsor: AirXpanders, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 17
States / cities: Greenbrae, California • Los Angeles, California • Orange, California + 12 more

Conditions: Breast Cancer
Interventions: Ribociclib, Anastrozole, Letrozole, Goserelin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more

Conditions: Alopecia Areata
Interventions: CTP-543 matching placebo, CTP-543; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Los Angeles, California + 19 more

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Localized Breast Carcinoma
Interventions: Best Practice, Patient Navigation, Referral, Survey Administration; Other · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer, NSCLC, Melanoma, Urothelial Carcinoma, MSI-H, Head and Neck Cancer
Interventions: APX005M; Drug
Lead sponsor: Apexigen America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Duarte, California • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
Interventions: Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more

Conditions: Breast Cancer
Interventions: 800 IU Vitamin D Supplement, 50,000 IU Vitamin D supplement; Drug
Lead sponsor: Mothaffar Rimawi; Other
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
Interventions: SBRT, IMRT, Brachytherapy; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Akt Inhibitor MK2206, Anastrozole, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Skin Cancer
Interventions: Fractional Laser and Chemical Peel; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
Interventions: Not listed
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 6 Months and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Cutaneous Melanoma, Brain Metastases
Interventions: Defactinib, Avutometinib, Encorafenib; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Iowa City, Iowa • Salt Lake City, Utah

Conditions: Breast Neoplasms, Neoplasms, Hormone-Dependent
Interventions: Atamestane, toremifene, letrozole; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more

Conditions: Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
Interventions: Nivolumab, Ipilimumab, Bicalutamide; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: New York, New York • Portland, Oregon

Conditions: Systemic Lupus Erythematosus
Interventions: BOS161721, Placebo; Drug
Lead sponsor: Boston Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 17
States / cities: Anniston, Alabama • El Cajon, California • Los Alamitos, California + 14 more

Conditions: Breast Neoplasms
Interventions: CC-486, Fulvestrant; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 44
States / cities: Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 35
States / cities: Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more

Conditions: Hereditary Angioedema Types I and II
Interventions: C1-esterase inhibitor; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more

Conditions: Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Interventions: vismodegib, Mohs surgery; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions: Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Validation of a Dermatology-Specific Treatment Satisfaction Instrument

Patient Controlled Tissue Expansion for Breast Reconstruction

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Oxybutynin Chloride in Managing Hot Flashes

High Dose Vitamin D vs Standard Dose Vitamin D Study

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy